Use of progenitor cells in pain management

M. J. Eaton, Stacey Quintero Wolfe, Eva Widerstrom-Noga

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

The use of progenitor/stem cells to modulate the sensory systems in chronic pain is a new field in translational research. This follows 30 years of non-human cell therapy approaches to elucidate which tissue source, cell phenotype, neurotransmitter, or peptide might be antinociceptive in models of pain. Stem or progenitor approaches have been tested in cardiac myopathies, liver dysfunction, stroke, and genetic abnormalities, but almost none have applied progenitor cells to the relief of neuropathic, pain. Perhaps the best studied neural progenitor cell line NT2, has recently resulted in two NT2-derived cell lines: hNT2.17, secreting the inhibitory neurotransmitters GABA and glycine; and hNT2.19, secreting the neurotransmitter serotonin. Each of these NT2-lines has demonstrated antinociceptive potential in models of SCI-related neuropathic pain, in peripheral neuropathy, and diabetic neuropathic pain. These human progenitors may prove to be useful in the relief of chronic pain and open the way to other regenerative approaches to pain management.

Original languageEnglish
Title of host publicationStem Cell and Regenerative Medicine
PublisherBentham Science Publishers Ltd.
Pages75-99
Number of pages25
ISBN (Print)9781608056972
DOIs
StatePublished - Dec 1 2010

Fingerprint

Pain Management
Neuralgia
Stem Cells
Neurotransmitter Agents
Chronic Pain
Cell Line
Translational Medical Research
Peripheral Nervous System Diseases
Muscular Diseases
Cell- and Tissue-Based Therapy
Glycine
gamma-Aminobutyric Acid
Liver Diseases
Serotonin
Stroke
Phenotype
Pain
Peptides

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Eaton, M. J., Wolfe, S. Q., & Widerstrom-Noga, E. (2010). Use of progenitor cells in pain management. In Stem Cell and Regenerative Medicine (pp. 75-99). Bentham Science Publishers Ltd.. https://doi.org/10.2174/978160805008611001010075

Use of progenitor cells in pain management. / Eaton, M. J.; Wolfe, Stacey Quintero; Widerstrom-Noga, Eva.

Stem Cell and Regenerative Medicine. Bentham Science Publishers Ltd., 2010. p. 75-99.

Research output: Chapter in Book/Report/Conference proceedingChapter

Eaton, MJ, Wolfe, SQ & Widerstrom-Noga, E 2010, Use of progenitor cells in pain management. in Stem Cell and Regenerative Medicine. Bentham Science Publishers Ltd., pp. 75-99. https://doi.org/10.2174/978160805008611001010075
Eaton MJ, Wolfe SQ, Widerstrom-Noga E. Use of progenitor cells in pain management. In Stem Cell and Regenerative Medicine. Bentham Science Publishers Ltd. 2010. p. 75-99 https://doi.org/10.2174/978160805008611001010075
Eaton, M. J. ; Wolfe, Stacey Quintero ; Widerstrom-Noga, Eva. / Use of progenitor cells in pain management. Stem Cell and Regenerative Medicine. Bentham Science Publishers Ltd., 2010. pp. 75-99
@inbook{89f46df183e54765ad84fabf44c6acc0,
title = "Use of progenitor cells in pain management",
abstract = "The use of progenitor/stem cells to modulate the sensory systems in chronic pain is a new field in translational research. This follows 30 years of non-human cell therapy approaches to elucidate which tissue source, cell phenotype, neurotransmitter, or peptide might be antinociceptive in models of pain. Stem or progenitor approaches have been tested in cardiac myopathies, liver dysfunction, stroke, and genetic abnormalities, but almost none have applied progenitor cells to the relief of neuropathic, pain. Perhaps the best studied neural progenitor cell line NT2, has recently resulted in two NT2-derived cell lines: hNT2.17, secreting the inhibitory neurotransmitters GABA and glycine; and hNT2.19, secreting the neurotransmitter serotonin. Each of these NT2-lines has demonstrated antinociceptive potential in models of SCI-related neuropathic pain, in peripheral neuropathy, and diabetic neuropathic pain. These human progenitors may prove to be useful in the relief of chronic pain and open the way to other regenerative approaches to pain management.",
author = "Eaton, {M. J.} and Wolfe, {Stacey Quintero} and Eva Widerstrom-Noga",
year = "2010",
month = "12",
day = "1",
doi = "10.2174/978160805008611001010075",
language = "English",
isbn = "9781608056972",
pages = "75--99",
booktitle = "Stem Cell and Regenerative Medicine",
publisher = "Bentham Science Publishers Ltd.",

}

TY - CHAP

T1 - Use of progenitor cells in pain management

AU - Eaton, M. J.

AU - Wolfe, Stacey Quintero

AU - Widerstrom-Noga, Eva

PY - 2010/12/1

Y1 - 2010/12/1

N2 - The use of progenitor/stem cells to modulate the sensory systems in chronic pain is a new field in translational research. This follows 30 years of non-human cell therapy approaches to elucidate which tissue source, cell phenotype, neurotransmitter, or peptide might be antinociceptive in models of pain. Stem or progenitor approaches have been tested in cardiac myopathies, liver dysfunction, stroke, and genetic abnormalities, but almost none have applied progenitor cells to the relief of neuropathic, pain. Perhaps the best studied neural progenitor cell line NT2, has recently resulted in two NT2-derived cell lines: hNT2.17, secreting the inhibitory neurotransmitters GABA and glycine; and hNT2.19, secreting the neurotransmitter serotonin. Each of these NT2-lines has demonstrated antinociceptive potential in models of SCI-related neuropathic pain, in peripheral neuropathy, and diabetic neuropathic pain. These human progenitors may prove to be useful in the relief of chronic pain and open the way to other regenerative approaches to pain management.

AB - The use of progenitor/stem cells to modulate the sensory systems in chronic pain is a new field in translational research. This follows 30 years of non-human cell therapy approaches to elucidate which tissue source, cell phenotype, neurotransmitter, or peptide might be antinociceptive in models of pain. Stem or progenitor approaches have been tested in cardiac myopathies, liver dysfunction, stroke, and genetic abnormalities, but almost none have applied progenitor cells to the relief of neuropathic, pain. Perhaps the best studied neural progenitor cell line NT2, has recently resulted in two NT2-derived cell lines: hNT2.17, secreting the inhibitory neurotransmitters GABA and glycine; and hNT2.19, secreting the neurotransmitter serotonin. Each of these NT2-lines has demonstrated antinociceptive potential in models of SCI-related neuropathic pain, in peripheral neuropathy, and diabetic neuropathic pain. These human progenitors may prove to be useful in the relief of chronic pain and open the way to other regenerative approaches to pain management.

UR - http://www.scopus.com/inward/record.url?scp=84873855377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873855377&partnerID=8YFLogxK

U2 - 10.2174/978160805008611001010075

DO - 10.2174/978160805008611001010075

M3 - Chapter

SN - 9781608056972

SP - 75

EP - 99

BT - Stem Cell and Regenerative Medicine

PB - Bentham Science Publishers Ltd.

ER -